Basic information Safety Supplier Related

Erlotinib D6 HCl

Basic information Safety Supplier Related

Erlotinib D6 HCl Basic information

Product Name:
Erlotinib D6 HCl
Synonyms:
  • Erlotinib D6
  • Erlotinib Hydrochloride Impurity G
  • [2H6]-Erlotinib Hydrochloride
  • CP-358774 D6 hydrochloride
  • NSC 718781 D6 hydrochloride
  • OSI-774 D6 hydrochloride
  • Erlotiniβ-d6 Hydrochloride
  • D6-Erlotinib hydrochloride
CAS:
1189953-78-3
MF:
C22H18ClD6N3O4
MW:
435.933630668
Mol File:
1189953-78-3.mol
More
Less

Erlotinib D6 HCl Chemical Properties

storage temp. 
Store at -20°C
solubility 
DMSO: slightly, heated,Methanol: slightly soluble
form 
A solid
color 
White to off-white
More
Less

Erlotinib D6 HCl Usage And Synthesis

Description

Erlotinib-d6 (hydrochloride) contains six deuterium atoms located on the methoxy group. It is intended for use as an internal standard for the quantification of erlotinib by GC- or LC-MS. Erlotinib is a tyrosine kinase inhibitor that acts on the epidermal growth factor receptor (EGFR), inhibiting EGFR-associated kinase activity (IC50 = 2.5 μM). This inhibits tumor growth in human head and neck carcinoma (HN5) tumor xenografts in mice with an ED50 value of 9 mg/kg. Erlotinib also suppresses cyclin-dependent kinase 2 (Cdk2) activity in breast cancer cells (IC50 = 4.6 μM) and JAK2 mutant JAK2V617F (IC50 = 5 μM), which is associated with polycythemia vera, idiopathic myelofibrosis, and essential thrombocythemia. Formulations containing erlotinib are used to treat certain forms of cancer, including non-small cell lung cancer.

Uses

Erlotinib D6 HCl is a Selective epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, Antineoplastic.;Labeled Erlotinib, intended for use as an internal standard for the quantification of Erlotinib by GC- or LC-mass spectrometry.

References

[1] LUCA GIANNI  Giacomo G. Targeting the epidermal growth factor receptor a new strategy in cancer treatment.[J]. I supplementi di Tumori?: official journal of Societa italiana di cancerologia ... [et al.], 2002, 1 4: S60-1.
[2] J D MOYER. Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase.[J]. Cancer research, 1997, 57 21: 4838-4848.
[3] ROY S HERBST  Paul A B. Targeting the epidermal growth factor receptor in non-small cell lung cancer.[J]. Clinical Cancer Research, 2003, 9 16 Pt 1: 5813-5824.

Erlotinib D6 HClSupplier

Daicel Chiral Technologies (China)CO.,LTD
Tel
021-50460086-9 15921403865
Email
han_yajun@dctc.daicel.com
ChemStrong Scientific Co.,Ltd
Tel
0755-0755-66853366 13670046396
Email
sales@chem-strong.com
Artis Biotech Co. Ltd.
Tel
028-67271278 18628360895
Email
sales@artisbio.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
Clearsynth Canada Inc.
Tel
+1.415.685.4395
Email
enquiry@clearsynth.com